| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Data Interpretation, Statistical | 9 | 2018 | 2691 | 1.210 |
Why?
|
| Clinical Trials as Topic | 19 | 2018 | 8002 | 0.830 |
Why?
|
| Breast Neoplasms | 40 | 2019 | 21012 | 0.800 |
Why?
|
| Rare Diseases | 2 | 2018 | 622 | 0.800 |
Why?
|
| AIDS-Related Opportunistic Infections | 15 | 2003 | 662 | 0.660 |
Why?
|
| Retinal Vein Occlusion | 6 | 1998 | 149 | 0.620 |
Why?
|
| Statistics, Nonparametric | 5 | 2016 | 2850 | 0.620 |
Why?
|
| Disease-Free Survival | 12 | 2016 | 6814 | 0.610 |
Why?
|
| Aromatase Inhibitors | 3 | 2016 | 513 | 0.570 |
Why?
|
| Neoplasms, Second Primary | 4 | 2019 | 1052 | 0.510 |
Why?
|
| Nitriles | 3 | 2016 | 971 | 0.510 |
Why?
|
| Proportional Hazards Models | 19 | 2016 | 12463 | 0.510 |
Why?
|
| Triazoles | 3 | 2016 | 903 | 0.500 |
Why?
|
| Pneumonia, Pneumocystis | 9 | 2000 | 242 | 0.500 |
Why?
|
| Laser Coagulation | 5 | 1998 | 330 | 0.500 |
Why?
|
| Acquired Immunodeficiency Syndrome | 16 | 2007 | 2199 | 0.500 |
Why?
|
| Survival Rate | 23 | 2019 | 12725 | 0.480 |
Why?
|
| Models, Statistical | 13 | 2018 | 5079 | 0.470 |
Why?
|
| Survival Analysis | 20 | 2018 | 10090 | 0.460 |
Why?
|
| Disease Progression | 14 | 2018 | 13506 | 0.430 |
Why?
|
| Research Design | 10 | 2022 | 6180 | 0.420 |
Why?
|
| Sample Size | 5 | 2022 | 841 | 0.410 |
Why?
|
| Bayes Theorem | 4 | 2019 | 2330 | 0.400 |
Why?
|
| Lymphedema | 2 | 2014 | 525 | 0.350 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 409 | 0.350 |
Why?
|
| Computer Security | 1 | 2011 | 261 | 0.330 |
Why?
|
| Receptor, erbB-2 | 8 | 2019 | 2557 | 0.320 |
Why?
|
| Antineoplastic Agents | 18 | 2016 | 13639 | 0.320 |
Why?
|
| Survivors | 3 | 2016 | 2371 | 0.320 |
Why?
|
| Biometry | 7 | 2015 | 563 | 0.320 |
Why?
|
| Neoplasms | 8 | 2019 | 22170 | 0.310 |
Why?
|
| Treatment Failure | 7 | 2007 | 2645 | 0.300 |
Why?
|
| Quinazolines | 4 | 2016 | 1371 | 0.300 |
Why?
|
| Quality of Life | 5 | 2018 | 13367 | 0.280 |
Why?
|
| Retinal Vein | 2 | 1998 | 47 | 0.280 |
Why?
|
| Computer Simulation | 14 | 2018 | 6240 | 0.270 |
Why?
|
| Xenobiotics | 1 | 2006 | 70 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1192 | 0.250 |
Why?
|
| Likelihood Functions | 6 | 2007 | 992 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 3514 | 0.250 |
Why?
|
| Humans | 201 | 2022 | 761504 | 0.240 |
Why?
|
| Cytomegalovirus Infections | 7 | 2002 | 831 | 0.230 |
Why?
|
| Choroid | 2 | 1998 | 360 | 0.230 |
Why?
|
| Osteoporosis | 1 | 2014 | 1606 | 0.230 |
Why?
|
| Registries | 6 | 2018 | 8224 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2019 | 9280 | 0.220 |
Why?
|
| Medical History Taking | 4 | 2019 | 774 | 0.220 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 1999 | 76 | 0.220 |
Why?
|
| Female | 142 | 2019 | 392644 | 0.210 |
Why?
|
| Treatment Outcome | 25 | 2018 | 64680 | 0.210 |
Why?
|
| Receptors, Progesterone | 4 | 2019 | 1129 | 0.210 |
Why?
|
| Colonoscopy | 4 | 2016 | 1394 | 0.210 |
Why?
|
| Data Collection | 3 | 2014 | 3322 | 0.200 |
Why?
|
| Carboplatin | 5 | 2015 | 794 | 0.200 |
Why?
|
| Mental Health | 1 | 2016 | 3250 | 0.200 |
Why?
|
| CA-125 Antigen | 2 | 2017 | 281 | 0.200 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 857 | 0.200 |
Why?
|
| Middle Aged | 98 | 2019 | 220895 | 0.190 |
Why?
|
| Macular Edema | 3 | 1997 | 374 | 0.190 |
Why?
|
| Adult | 92 | 2019 | 221177 | 0.190 |
Why?
|
| Regression Analysis | 6 | 2008 | 6343 | 0.180 |
Why?
|
| Heart Diseases | 1 | 2014 | 2781 | 0.180 |
Why?
|
| Aged | 78 | 2018 | 169289 | 0.180 |
Why?
|
| Cytomegalovirus | 6 | 2002 | 756 | 0.170 |
Why?
|
| Longitudinal Studies | 7 | 2010 | 14605 | 0.170 |
Why?
|
| National Health Programs | 2 | 2013 | 440 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2019 | 10209 | 0.170 |
Why?
|
| Ethics, Medical | 2 | 1997 | 783 | 0.170 |
Why?
|
| Markov Chains | 4 | 2015 | 966 | 0.170 |
Why?
|
| Hodgkin Disease | 3 | 2008 | 1378 | 0.170 |
Why?
|
| Receptors, Estrogen | 4 | 2019 | 2208 | 0.170 |
Why?
|
| Internet | 1 | 2011 | 3092 | 0.160 |
Why?
|
| Control Groups | 1 | 2019 | 104 | 0.160 |
Why?
|
| Radiotherapy | 6 | 2014 | 1499 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2015 | 11742 | 0.160 |
Why?
|
| Time Factors | 29 | 2018 | 39967 | 0.150 |
Why?
|
| Toilet Training | 1 | 2017 | 18 | 0.150 |
Why?
|
| Wounds and Injuries | 4 | 2015 | 2491 | 0.150 |
Why?
|
| Neoplasm Staging | 14 | 2019 | 11121 | 0.150 |
Why?
|
| Candidiasis | 2 | 1999 | 365 | 0.150 |
Why?
|
| Algorithms | 10 | 2017 | 14031 | 0.150 |
Why?
|
| Enuresis | 1 | 2017 | 50 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 443 | 0.150 |
Why?
|
| Data Display | 1 | 2018 | 175 | 0.150 |
Why?
|
| Genetic Counseling | 2 | 2016 | 627 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 6 | 2002 | 420 | 0.150 |
Why?
|
| Pentamidine | 4 | 2000 | 44 | 0.150 |
Why?
|
| Models, Biological | 7 | 2002 | 9469 | 0.140 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 926 | 0.140 |
Why?
|
| Treatment Refusal | 1 | 2000 | 429 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2358 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2001 | 1085 | 0.140 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2014 | 491 | 0.130 |
Why?
|
| Ovarian Neoplasms | 6 | 2017 | 4876 | 0.130 |
Why?
|
| Genes, BRCA1 | 3 | 2007 | 764 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2016 | 857 | 0.130 |
Why?
|
| Male | 100 | 2019 | 360804 | 0.130 |
Why?
|
| Moral Obligations | 1 | 1997 | 93 | 0.130 |
Why?
|
| Proteinuria | 2 | 2011 | 607 | 0.130 |
Why?
|
| Zidovudine | 6 | 1999 | 624 | 0.130 |
Why?
|
| Research | 3 | 2015 | 1982 | 0.130 |
Why?
|
| Mycoses | 2 | 1996 | 386 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2014 | 17904 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2011 | 9318 | 0.130 |
Why?
|
| Skull Base Neoplasms | 4 | 2001 | 270 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2018 | 590 | 0.130 |
Why?
|
| Family Health | 3 | 2011 | 1257 | 0.130 |
Why?
|
| Early Detection of Cancer | 5 | 2017 | 3201 | 0.130 |
Why?
|
| Neoplasms, Experimental | 3 | 1991 | 1229 | 0.130 |
Why?
|
| Anti-Infective Agents | 5 | 2002 | 983 | 0.130 |
Why?
|
| Amidines | 1 | 2015 | 29 | 0.130 |
Why?
|
| BRCA2 Protein | 4 | 2015 | 805 | 0.120 |
Why?
|
| Employee Performance Appraisal | 1 | 2015 | 86 | 0.120 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2015 | 60 | 0.120 |
Why?
|
| Follow-Up Studies | 26 | 2019 | 39106 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3778 | 0.120 |
Why?
|
| Diabetic Retinopathy | 3 | 2011 | 1274 | 0.120 |
Why?
|
| Aged, 80 and over | 28 | 2018 | 58976 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2017 | 356 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2012 | 592 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 2011 | 2469 | 0.120 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 2759 | 0.120 |
Why?
|
| Multivariate Analysis | 8 | 2013 | 12059 | 0.120 |
Why?
|
| Cisplatin | 6 | 2015 | 1651 | 0.120 |
Why?
|
| Colorectal Neoplasms | 5 | 2014 | 6935 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2002 | 2690 | 0.120 |
Why?
|
| Fluorescein Angiography | 6 | 2000 | 1059 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2012 | 942 | 0.110 |
Why?
|
| Benzylamines | 1 | 2015 | 247 | 0.110 |
Why?
|
| Virus Shedding | 2 | 2007 | 111 | 0.110 |
Why?
|
| Developed Countries | 1 | 2016 | 449 | 0.110 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 9420 | 0.110 |
Why?
|
| Genes, BRCA2 | 2 | 2007 | 601 | 0.110 |
Why?
|
| Disclosure | 2 | 1997 | 748 | 0.110 |
Why?
|
| BRCA1 Protein | 4 | 2015 | 1155 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 517 | 0.110 |
Why?
|
| Clotrimazole | 3 | 1999 | 76 | 0.110 |
Why?
|
| Risk Management | 1 | 1997 | 558 | 0.110 |
Why?
|
| Personnel Management | 1 | 2013 | 52 | 0.110 |
Why?
|
| Paget Disease, Extramammary | 2 | 2003 | 51 | 0.110 |
Why?
|
| Dapsone | 3 | 1999 | 56 | 0.100 |
Why?
|
| Lung Neoplasms | 17 | 2008 | 13380 | 0.100 |
Why?
|
| Incidence | 10 | 2022 | 21353 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 7594 | 0.100 |
Why?
|
| Health Services Accessibility | 4 | 2016 | 5440 | 0.100 |
Why?
|
| Fluconazole | 3 | 1999 | 157 | 0.100 |
Why?
|
| Nervous System | 1 | 2016 | 545 | 0.100 |
Why?
|
| Chordoma | 4 | 2001 | 347 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 258 | 0.100 |
Why?
|
| Mastectomy | 3 | 2016 | 1822 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2019 | 795 | 0.100 |
Why?
|
| Receptors, Steroid | 2 | 2017 | 156 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 243 | 0.100 |
Why?
|
| Women's Health Services | 1 | 2012 | 88 | 0.100 |
Why?
|
| Malpractice | 1 | 1997 | 556 | 0.100 |
Why?
|
| Carcinoma, Bronchogenic | 3 | 1986 | 87 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 380 | 0.100 |
Why?
|
| Risk | 4 | 2019 | 9610 | 0.100 |
Why?
|
| Mutation | 7 | 2015 | 30052 | 0.100 |
Why?
|
| Health Planning | 1 | 2013 | 230 | 0.100 |
Why?
|
| Prevalence | 6 | 2018 | 15732 | 0.100 |
Why?
|
| Glioma | 6 | 2005 | 3455 | 0.090 |
Why?
|
| Risk Factors | 23 | 2017 | 74206 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2014 | 4026 | 0.090 |
Why?
|
| Biostatistics | 1 | 2013 | 164 | 0.090 |
Why?
|
| Albuminuria | 2 | 2007 | 657 | 0.090 |
Why?
|
| Fatigue | 1 | 2018 | 1552 | 0.090 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2019 | 1469 | 0.090 |
Why?
|
| Carcinogens | 2 | 1991 | 452 | 0.090 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2011 | 105 | 0.090 |
Why?
|
| Macula Lutea | 1 | 1992 | 177 | 0.090 |
Why?
|
| Prospective Studies | 23 | 2022 | 54425 | 0.090 |
Why?
|
| Brain Neoplasms | 10 | 2005 | 9031 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2014 | 1271 | 0.090 |
Why?
|
| Liver | 1 | 2006 | 7529 | 0.090 |
Why?
|
| Informed Consent | 2 | 1998 | 1008 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2529 | 0.090 |
Why?
|
| Indians, North American | 1 | 2014 | 352 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2006 | 12128 | 0.090 |
Why?
|
| Mycobacterium avium Complex | 2 | 1999 | 60 | 0.090 |
Why?
|
| Fundus Oculi | 3 | 1998 | 556 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2012 | 1727 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2008 | 549 | 0.080 |
Why?
|
| Diphosphates | 1 | 1989 | 84 | 0.080 |
Why?
|
| Antifungal Agents | 3 | 1999 | 752 | 0.080 |
Why?
|
| Technetium | 1 | 1989 | 317 | 0.080 |
Why?
|
| Gastroenterology | 1 | 2016 | 577 | 0.080 |
Why?
|
| Prognosis | 25 | 2015 | 29625 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1996 | 807 | 0.080 |
Why?
|
| Procarbazine | 5 | 1996 | 172 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 1989 | 91 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 3 | 2001 | 548 | 0.080 |
Why?
|
| Hemangioma, Cavernous | 1 | 1989 | 107 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2007 | 3415 | 0.080 |
Why?
|
| Risk Assessment | 10 | 2012 | 23995 | 0.080 |
Why?
|
| Monte Carlo Method | 5 | 2015 | 1258 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 310 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 5 | 1997 | 1164 | 0.080 |
Why?
|
| Porphyrins | 1 | 2010 | 352 | 0.080 |
Why?
|
| Medical Errors | 1 | 1997 | 1263 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2827 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1505 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 517 | 0.080 |
Why?
|
| Human papillomavirus 16 | 1 | 2010 | 267 | 0.080 |
Why?
|
| Antiviral Agents | 4 | 2007 | 3060 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2003 | 2571 | 0.070 |
Why?
|
| Predictive Value of Tests | 10 | 2013 | 15266 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 310 | 0.070 |
Why?
|
| Penetrance | 2 | 2008 | 383 | 0.070 |
Why?
|
| Didanosine | 2 | 1999 | 151 | 0.070 |
Why?
|
| Methotrexate | 7 | 2005 | 1719 | 0.070 |
Why?
|
| Pneumocystis Infections | 1 | 2007 | 10 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 3 | 2012 | 5368 | 0.070 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2009 | 194 | 0.070 |
Why?
|
| Prostatic Neoplasms | 3 | 2011 | 11118 | 0.070 |
Why?
|
| Photons | 3 | 2000 | 589 | 0.070 |
Why?
|
| Sputum | 2 | 1999 | 506 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2015 | 1203 | 0.070 |
Why?
|
| Hospitalization | 4 | 2022 | 10723 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 785 | 0.070 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2007 | 174 | 0.070 |
Why?
|
| Pneumocystis carinii | 1 | 2007 | 72 | 0.070 |
Why?
|
| Genetic Testing | 4 | 2016 | 3537 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2009 | 4511 | 0.070 |
Why?
|
| Cyclophosphamide | 10 | 2005 | 2218 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1989 | 718 | 0.070 |
Why?
|
| Mass Screening | 5 | 2014 | 5428 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 1989 | 422 | 0.070 |
Why?
|
| Mucins | 1 | 2009 | 568 | 0.070 |
Why?
|
| Bulimia | 2 | 2000 | 400 | 0.070 |
Why?
|
| CA-19-9 Antigen | 1 | 2006 | 106 | 0.070 |
Why?
|
| United States | 15 | 2019 | 72334 | 0.070 |
Why?
|
| Nursing Staff, Hospital | 1 | 1989 | 348 | 0.070 |
Why?
|
| User-Computer Interface | 2 | 2011 | 1400 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2017 | 899 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2B1 | 1 | 2005 | 21 | 0.060 |
Why?
|
| Phenobarbital | 1 | 2006 | 191 | 0.060 |
Why?
|
| Salvage Therapy | 4 | 2009 | 1264 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 1989 | 514 | 0.060 |
Why?
|
| Carboxylesterase | 1 | 2005 | 31 | 0.060 |
Why?
|
| Primaquine | 2 | 1996 | 28 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 2007 | 242 | 0.060 |
Why?
|
| Thymoma | 2 | 2000 | 188 | 0.060 |
Why?
|
| Health Services Research | 1 | 2013 | 1812 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 244 | 0.060 |
Why?
|
| Germ-Line Mutation | 3 | 2000 | 1858 | 0.060 |
Why?
|
| Job Satisfaction | 1 | 1989 | 544 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2005 | 3595 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 1989 | 601 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2016 | 2498 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2000 | 655 | 0.060 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 242 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2008 | 701 | 0.060 |
Why?
|
| Clindamycin | 2 | 1996 | 139 | 0.060 |
Why?
|
| Personal Satisfaction | 1 | 1989 | 644 | 0.060 |
Why?
|
| Immunocompetence | 1 | 2005 | 138 | 0.060 |
Why?
|
| Models, Genetic | 3 | 2015 | 3442 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 2078 | 0.060 |
Why?
|
| Radiation Injuries | 4 | 2000 | 1189 | 0.060 |
Why?
|
| Loss of Heterozygosity | 2 | 2015 | 662 | 0.060 |
Why?
|
| Thymus Neoplasms | 2 | 2000 | 274 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2015 | 2865 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3712 | 0.060 |
Why?
|
| Developing Countries | 1 | 2016 | 2885 | 0.060 |
Why?
|
| ras Proteins | 1 | 2009 | 1054 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 2416 | 0.060 |
Why?
|
| Serotonin | 2 | 2000 | 1041 | 0.060 |
Why?
|
| Ischemia | 1 | 1992 | 1882 | 0.060 |
Why?
|
| Parents | 1 | 2017 | 3563 | 0.060 |
Why?
|
| Health Promotion | 2 | 2016 | 2214 | 0.060 |
Why?
|
| HIV Infections | 9 | 2000 | 17351 | 0.060 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 16981 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 646 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 3 | 2000 | 1702 | 0.050 |
Why?
|
| Pain | 1 | 2018 | 5073 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1405 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 8547 | 0.050 |
Why?
|
| Genetic Services | 1 | 2003 | 13 | 0.050 |
Why?
|
| Vincristine | 5 | 2002 | 1036 | 0.050 |
Why?
|
| Personal Autonomy | 2 | 1998 | 304 | 0.050 |
Why?
|
| Neoplasm Metastasis | 8 | 2014 | 4915 | 0.050 |
Why?
|
| Doxorubicin | 9 | 2002 | 2224 | 0.050 |
Why?
|
| Teniposide | 1 | 2002 | 11 | 0.050 |
Why?
|
| Interviews as Topic | 5 | 2014 | 2696 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 5671 | 0.050 |
Why?
|
| HLA-DQ Antigens | 2 | 2000 | 191 | 0.050 |
Why?
|
| Feces | 2 | 1999 | 1497 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2510 | 0.050 |
Why?
|
| Age Factors | 7 | 2014 | 18395 | 0.050 |
Why?
|
| HIV-1 | 3 | 2000 | 6863 | 0.050 |
Why?
|
| Adolescent | 20 | 2013 | 88319 | 0.050 |
Why?
|
| Brain Stem | 2 | 1999 | 858 | 0.050 |
Why?
|
| Adenocarcinoma | 4 | 2006 | 6346 | 0.050 |
Why?
|
| Tachycardia | 3 | 1991 | 600 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2008 | 2341 | 0.050 |
Why?
|
| Fenfluramine | 2 | 2000 | 58 | 0.050 |
Why?
|
| Leukocytes | 1 | 2010 | 2026 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2003 | 2927 | 0.050 |
Why?
|
| Jews | 3 | 2006 | 356 | 0.050 |
Why?
|
| Mathematics | 1 | 2003 | 707 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1940 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2002 | 232 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2006 | 710 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 15936 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2019 | 41487 | 0.050 |
Why?
|
| Aerosols | 3 | 2000 | 635 | 0.050 |
Why?
|
| HLA-DR Antigens | 2 | 2000 | 602 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2006 | 811 | 0.050 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 20098 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2002 | 188 | 0.050 |
Why?
|
| Melanoma | 4 | 2002 | 5709 | 0.050 |
Why?
|
| Estrogens | 1 | 2008 | 1522 | 0.050 |
Why?
|
| Gene Expression | 3 | 2010 | 7581 | 0.050 |
Why?
|
| Paclitaxel | 5 | 2005 | 1732 | 0.050 |
Why?
|
| Mitomycins | 4 | 1989 | 46 | 0.050 |
Why?
|
| Retrospective Studies | 22 | 2013 | 80636 | 0.050 |
Why?
|
| Drug Evaluation | 7 | 1992 | 641 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2220 | 0.050 |
Why?
|
| Quality of Health Care | 2 | 2012 | 4330 | 0.050 |
Why?
|
| Heterozygote | 4 | 2015 | 2787 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 4016 | 0.050 |
Why?
|
| Mexico | 2 | 2014 | 764 | 0.050 |
Why?
|
| Blood Donors | 2 | 1994 | 345 | 0.050 |
Why?
|
| Truth Disclosure | 2 | 1997 | 434 | 0.050 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2001 | 89 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 11903 | 0.050 |
Why?
|
| Prolactin | 2 | 2000 | 625 | 0.040 |
Why?
|
| Carcinogenicity Tests | 2 | 1991 | 38 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1985 | 1334 | 0.040 |
Why?
|
| Thymosin | 1 | 2000 | 47 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 9177 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1516 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2016 | 4792 | 0.040 |
Why?
|
| Genotype | 6 | 2014 | 12990 | 0.040 |
Why?
|
| Erythrocytes | 1 | 1989 | 2413 | 0.040 |
Why?
|
| Formamides | 2 | 1990 | 21 | 0.040 |
Why?
|
| Macrophages | 1 | 2015 | 5769 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2001 | 218 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7856 | 0.040 |
Why?
|
| Pneumocystis | 1 | 1999 | 55 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2000 | 698 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2005 | 753 | 0.040 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 286 | 0.040 |
Why?
|
| Naphthoquinones | 1 | 1999 | 58 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2000 | 252 | 0.040 |
Why?
|
| Logistic Models | 4 | 2013 | 13255 | 0.040 |
Why?
|
| Spiro Compounds | 2 | 1990 | 68 | 0.040 |
Why?
|
| Ophthalmoscopy | 2 | 2000 | 171 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2009 | 2057 | 0.040 |
Why?
|
| Probability | 2 | 2005 | 2477 | 0.040 |
Why?
|
| Chondrosarcoma | 2 | 2001 | 296 | 0.040 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2000 | 209 | 0.040 |
Why?
|
| Radiotherapy Dosage | 6 | 2005 | 2898 | 0.040 |
Why?
|
| Vinblastine | 4 | 1989 | 488 | 0.040 |
Why?
|
| Massachusetts | 6 | 2008 | 8830 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 4243 | 0.040 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2000 | 151 | 0.040 |
Why?
|
| Fovea Centralis | 1 | 2000 | 126 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2008 | 5315 | 0.040 |
Why?
|
| Recurrence | 7 | 1999 | 8465 | 0.040 |
Why?
|
| Analysis of Variance | 7 | 2003 | 6228 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 629 | 0.040 |
Why?
|
| Brazil | 2 | 2013 | 1230 | 0.040 |
Why?
|
| Child | 14 | 2017 | 80153 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2002 | 617 | 0.040 |
Why?
|
| Recombinant Proteins | 7 | 1997 | 6534 | 0.040 |
Why?
|
| Skin Neoplasms | 4 | 2008 | 5821 | 0.040 |
Why?
|
| China | 2 | 2014 | 2369 | 0.040 |
Why?
|
| Mitomycin | 3 | 1988 | 263 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 940 | 0.040 |
Why?
|
| Drug Therapy, Combination | 6 | 1999 | 6310 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2001 | 635 | 0.040 |
Why?
|
| Paternalism | 1 | 1998 | 47 | 0.040 |
Why?
|
| Meningeal Neoplasms | 2 | 2000 | 1248 | 0.040 |
Why?
|
| Breast | 2 | 2011 | 1967 | 0.040 |
Why?
|
| Remission, Spontaneous | 2 | 2003 | 384 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2007 | 2242 | 0.040 |
Why?
|
| Burns | 1 | 2009 | 1882 | 0.040 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14666 | 0.040 |
Why?
|
| Young Adult | 7 | 2015 | 59243 | 0.040 |
Why?
|
| Visual Acuity | 3 | 2000 | 2672 | 0.040 |
Why?
|
| Etoposide | 5 | 1995 | 634 | 0.040 |
Why?
|
| Multiple Organ Failure | 2 | 2010 | 387 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 1999 | 224 | 0.040 |
Why?
|
| Random Allocation | 10 | 1992 | 2395 | 0.040 |
Why?
|
| Combined Modality Therapy | 7 | 2010 | 8529 | 0.040 |
Why?
|
| Hypoglycemia | 2 | 1995 | 883 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.040 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 4853 | 0.040 |
Why?
|
| Genes, MHC Class II | 1 | 1998 | 434 | 0.040 |
Why?
|
| Whistleblowing | 1 | 1997 | 7 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 2645 | 0.040 |
Why?
|
| Radionuclide Imaging | 4 | 2007 | 1972 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 1935 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 205 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2651 | 0.040 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12341 | 0.040 |
Why?
|
| Wireless Technology | 1 | 2017 | 98 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 1998 | 279 | 0.030 |
Why?
|
| Lomustine | 1 | 1996 | 60 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2006 | 2331 | 0.030 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 7827 | 0.030 |
Why?
|
| Social Values | 1 | 1998 | 225 | 0.030 |
Why?
|
| Neoplasm Proteins | 3 | 2002 | 3617 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 5146 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2002 | 727 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2002 | 1076 | 0.030 |
Why?
|
| Bone Diseases | 1 | 2000 | 418 | 0.030 |
Why?
|
| Compensation and Redress | 1 | 1997 | 66 | 0.030 |
Why?
|
| Alleles | 2 | 2014 | 6863 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1999 | 479 | 0.030 |
Why?
|
| Maryland | 1 | 1997 | 277 | 0.030 |
Why?
|
| Protons | 2 | 2000 | 1116 | 0.030 |
Why?
|
| Taxoids | 1 | 2000 | 668 | 0.030 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1996 | 71 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 2538 | 0.030 |
Why?
|
| Adenoma | 1 | 2007 | 2160 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 3358 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 1993 | 866 | 0.030 |
Why?
|
| Hyperglycemia | 2 | 1995 | 1376 | 0.030 |
Why?
|
| Bacterial Infections | 2 | 2002 | 1390 | 0.030 |
Why?
|
| Age of Onset | 5 | 2007 | 3305 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1626 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2011 | 7967 | 0.030 |
Why?
|
| Organometallic Compounds | 2 | 1990 | 647 | 0.030 |
Why?
|
| Hypothalamus | 1 | 2001 | 999 | 0.030 |
Why?
|
| Genome, Human | 1 | 2008 | 4425 | 0.030 |
Why?
|
| Viruses | 1 | 1999 | 375 | 0.030 |
Why?
|
| Hormones | 2 | 2000 | 869 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2298 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 385 | 0.030 |
Why?
|
| Animals | 14 | 2017 | 168459 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 287 | 0.030 |
Why?
|
| Proteins | 3 | 2006 | 6032 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10445 | 0.030 |
Why?
|
| Myocardial Infarction | 8 | 1990 | 11460 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2015 | 145 | 0.030 |
Why?
|
| Benzoquinones | 2 | 1985 | 198 | 0.030 |
Why?
|
| Blood Glucose | 3 | 2007 | 6391 | 0.030 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1999 | 328 | 0.030 |
Why?
|
| Progesterone | 3 | 1988 | 742 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2015 | 166 | 0.030 |
Why?
|
| South Dakota | 1 | 2014 | 32 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1996 | 165 | 0.030 |
Why?
|
| Genetic Vectors | 3 | 2000 | 3395 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1998 | 803 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 1996 | 182 | 0.030 |
Why?
|
| Macular Degeneration | 2 | 2000 | 1007 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 1993 | 774 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1998 | 983 | 0.030 |
Why?
|
| Rupture | 1 | 1996 | 443 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 1995 | 378 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 891 | 0.030 |
Why?
|
| Remission Induction | 6 | 2000 | 2396 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1999 | 960 | 0.030 |
Why?
|
| Social Responsibility | 1 | 1997 | 386 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 1998 | 369 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 1989 | 4481 | 0.030 |
Why?
|
| Amino Acids | 1 | 2000 | 1718 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2001 | 882 | 0.030 |
Why?
|
| West Indies | 1 | 2013 | 32 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 582 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1993 | 1624 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 1374 | 0.030 |
Why?
|
| Head | 1 | 1999 | 924 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 2 | 2005 | 2895 | 0.030 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2013 | 82 | 0.030 |
Why?
|
| Eye | 1 | 1997 | 712 | 0.030 |
Why?
|
| Anonymous Testing | 1 | 1992 | 9 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2006 | 12795 | 0.030 |
Why?
|
| Consent Forms | 1 | 1993 | 55 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 1206 | 0.030 |
Why?
|
| Nogalamycin | 1 | 1992 | 2 | 0.030 |
Why?
|
| Child, Preschool | 7 | 2017 | 42230 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 374 | 0.030 |
Why?
|
| Isoxazoles | 1 | 1994 | 232 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 1994 | 220 | 0.030 |
Why?
|
| Authorship | 1 | 2015 | 284 | 0.030 |
Why?
|
| Polyarteritis Nodosa | 1 | 1973 | 70 | 0.030 |
Why?
|
| Lymphokines | 1 | 1995 | 927 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 809 | 0.030 |
Why?
|
| Faculty | 1 | 2015 | 384 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 507 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 1768 | 0.020 |
Why?
|
| Women | 1 | 1993 | 223 | 0.020 |
Why?
|
| Public Sector | 1 | 2013 | 267 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5840 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1062 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1996 | 775 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4320 | 0.020 |
Why?
|
| Trust | 1 | 1997 | 530 | 0.020 |
Why?
|
| Meningioma | 1 | 2000 | 1218 | 0.020 |
Why?
|
| Patient Participation | 2 | 1993 | 1444 | 0.020 |
Why?
|
| Blood Banks | 1 | 1992 | 108 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1996 | 921 | 0.020 |
Why?
|
| Latin America | 1 | 2013 | 410 | 0.020 |
Why?
|
| Coronary Disease | 5 | 1989 | 5914 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2707 | 0.020 |
Why?
|
| Thallium Radioisotopes | 2 | 1988 | 138 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 1995 | 479 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2017 | 8631 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 954 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2016 | 955 | 0.020 |
Why?
|
| Hallucinations | 1 | 1994 | 366 | 0.020 |
Why?
|
| Meningitis | 1 | 1993 | 217 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 3615 | 0.020 |
Why?
|
| Mammography | 2 | 2012 | 2430 | 0.020 |
Why?
|
| Fibronectins | 2 | 2010 | 723 | 0.020 |
Why?
|
| Morbidity | 2 | 2011 | 1750 | 0.020 |
Why?
|
| Aprotinin | 1 | 1991 | 94 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2001 | 11076 | 0.020 |
Why?
|
| Inflammation | 2 | 2010 | 10773 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
| Parenting | 1 | 1997 | 701 | 0.020 |
Why?
|
| Heart Arrest | 2 | 1993 | 1514 | 0.020 |
Why?
|
| Organoplatinum Compounds | 2 | 1989 | 407 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1999 | 5671 | 0.020 |
Why?
|
| Family | 2 | 2014 | 3194 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2017 | 5247 | 0.020 |
Why?
|
| Private Sector | 1 | 2013 | 398 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1998 | 1695 | 0.020 |
Why?
|
| Arm | 1 | 2013 | 589 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1171 | 0.020 |
Why?
|
| Exercise Test | 2 | 1988 | 2127 | 0.020 |
Why?
|
| Retinal Diseases | 1 | 1996 | 705 | 0.020 |
Why?
|
| Professional Role | 1 | 2013 | 314 | 0.020 |
Why?
|
| Gene Frequency | 2 | 2008 | 3606 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 463 | 0.020 |
Why?
|
| Hospital Bed Capacity, under 100 | 1 | 1989 | 6 | 0.020 |
Why?
|
| Infusions, Intravenous | 4 | 2002 | 2219 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1997 | 1051 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 22169 | 0.020 |
Why?
|
| DNA Mutational Analysis | 3 | 2010 | 4111 | 0.020 |
Why?
|
| Professional Competence | 1 | 2013 | 431 | 0.020 |
Why?
|
| Otosclerosis | 1 | 1991 | 113 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1997 | 1092 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2010 | 1755 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2013 | 3242 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3384 | 0.020 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 1989 | 45 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2013 | 546 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1999 | 1545 | 0.020 |
Why?
|
| Sotalol | 1 | 1989 | 47 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 1995 | 795 | 0.020 |
Why?
|
| Germanium | 1 | 1989 | 7 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2426 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3602 | 0.020 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 1991 | 144 | 0.020 |
Why?
|
| Idarubicin | 1 | 1989 | 59 | 0.020 |
Why?
|
| Personnel Turnover | 1 | 1989 | 88 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2011 | 554 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2455 | 0.020 |
Why?
|
| Aziridines | 2 | 1985 | 21 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 1813 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 6075 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3335 | 0.020 |
Why?
|
| Hemorrhage | 2 | 1991 | 3424 | 0.020 |
Why?
|
| Diabetic Nephropathies | 2 | 2007 | 973 | 0.020 |
Why?
|
| Lod Score | 1 | 2008 | 600 | 0.020 |
Why?
|
| Sudden Infant Death | 1 | 1991 | 292 | 0.020 |
Why?
|
| Placebos | 3 | 2000 | 1667 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2014 | 1173 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1170 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1999 | 826 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1989 | 615 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2012 | 567 | 0.020 |
Why?
|
| Angina Pectoris | 2 | 1988 | 959 | 0.020 |
Why?
|
| Premenopause | 1 | 2011 | 1039 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 1961 | 0.020 |
Why?
|
| Electrocardiography | 6 | 1991 | 6377 | 0.020 |
Why?
|
| Menarche | 1 | 2010 | 532 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2010 | 9646 | 0.020 |
Why?
|
| Affect | 1 | 1995 | 1486 | 0.020 |
Why?
|
| Referral and Consultation | 2 | 1997 | 3600 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 1991 | 653 | 0.020 |
Why?
|
| Parity | 1 | 2010 | 927 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1994 | 1088 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2013 | 22176 | 0.020 |
Why?
|
| Ventricular Fibrillation | 1 | 1989 | 537 | 0.020 |
Why?
|
| Physician-Patient Relations | 2 | 1997 | 3249 | 0.020 |
Why?
|
| Patient Selection | 2 | 2016 | 4244 | 0.020 |
Why?
|
| Sex Factors | 4 | 2008 | 10552 | 0.020 |
Why?
|
| Retroviridae | 2 | 2000 | 850 | 0.020 |
Why?
|
| Anti-HIV Agents | 2 | 1999 | 4527 | 0.020 |
Why?
|
| Mice | 4 | 2015 | 81525 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 2469 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1988 | 685 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4575 | 0.020 |
Why?
|
| Myocardium | 2 | 1990 | 4726 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 573 | 0.020 |
Why?
|
| Amifostine | 1 | 2005 | 40 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 903 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4124 | 0.020 |
Why?
|
| Connecticut | 2 | 1996 | 364 | 0.020 |
Why?
|
| Hemophilia A | 2 | 1999 | 360 | 0.020 |
Why?
|
| Crohn Disease | 1 | 1998 | 2279 | 0.020 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2093 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 1998 | 535 | 0.020 |
Why?
|
| Biotransformation | 1 | 2005 | 166 | 0.020 |
Why?
|
| Azirines | 1 | 1985 | 30 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 10766 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1995 | 3208 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 1998 | 638 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6484 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2007 | 362 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1993 | 1555 | 0.020 |
Why?
|
| Electric Countershock | 1 | 1988 | 533 | 0.020 |
Why?
|
| Frameshift Mutation | 2 | 1997 | 392 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 1386 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2000 | 561 | 0.010 |
Why?
|
| Colon | 1 | 1973 | 1792 | 0.010 |
Why?
|
| Phenotype | 2 | 2015 | 16591 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 1971 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2007 | 957 | 0.010 |
Why?
|
| Body Weight | 3 | 1997 | 4618 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1996 | 2244 | 0.010 |
Why?
|
| Goals | 1 | 1989 | 711 | 0.010 |
Why?
|
| Defibrillators, Implantable | 1 | 1993 | 1490 | 0.010 |
Why?
|
| Transplantation, Autologous | 2 | 1999 | 2115 | 0.010 |
Why?
|
| New York | 2 | 1996 | 874 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2013 | 1247 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2811 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1991 | 1336 | 0.010 |
Why?
|
| Prodrugs | 1 | 2005 | 261 | 0.010 |
Why?
|
| Menopause | 1 | 2011 | 1646 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1996 | 4936 | 0.010 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 15842 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1667 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2010 | 2202 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 883 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1986 | 864 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1986 | 672 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4544 | 0.010 |
Why?
|
| Hemostasis | 3 | 1991 | 467 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1991 | 1490 | 0.010 |
Why?
|
| Reward | 1 | 1989 | 971 | 0.010 |
Why?
|
| Pregnancy | 3 | 2014 | 29874 | 0.010 |
Why?
|
| Postmenopause | 1 | 2011 | 2513 | 0.010 |
Why?
|
| Sequence Deletion | 2 | 1997 | 1494 | 0.010 |
Why?
|
| DNA Primers | 2 | 1997 | 2819 | 0.010 |
Why?
|
| Aspirin | 2 | 1991 | 3133 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23445 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 161 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 1988 | 628 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1991 | 2064 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2013 | 1852 | 0.010 |
Why?
|
| Camptothecin | 1 | 2005 | 591 | 0.010 |
Why?
|
| Point Mutation | 2 | 1997 | 1595 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1745 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3466 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 197 | 0.010 |
Why?
|
| Base Sequence | 3 | 1997 | 12441 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 1998 | 7390 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 6132 | 0.010 |
Why?
|
| Genetic Markers | 2 | 1998 | 2601 | 0.010 |
Why?
|
| Bleeding Time | 2 | 1991 | 83 | 0.010 |
Why?
|
| Medical Records | 2 | 1996 | 1408 | 0.010 |
Why?
|
| Government Programs | 1 | 2003 | 279 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 4369 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 5791 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3810 | 0.010 |
Why?
|
| Leukopenia | 2 | 1995 | 213 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 2003 | 263 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 1784 | 0.010 |
Why?
|
| Lipofuscin | 1 | 2000 | 40 | 0.010 |
Why?
|
| Hyperprolactinemia | 1 | 2001 | 124 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5871 | 0.010 |
Why?
|
| Atovaquone | 1 | 1999 | 56 | 0.010 |
Why?
|
| Rats, Nude | 1 | 1999 | 105 | 0.010 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1999 | 30 | 0.010 |
Why?
|
| Coronary Angiography | 2 | 1988 | 4471 | 0.010 |
Why?
|
| Primary Health Care | 1 | 1996 | 4686 | 0.010 |
Why?
|
| Brain Abscess | 1 | 2000 | 120 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 280 | 0.010 |
Why?
|
| Brain | 2 | 2005 | 27112 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 793 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2979 | 0.010 |
Why?
|
| Cross-Sectional Studies | 4 | 2007 | 26125 | 0.010 |
Why?
|
| HLA-DP Antigens | 1 | 1998 | 25 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 1988 | 2084 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 2000 | 231 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2011 | 36426 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1988 | 2244 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1999 | 228 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 2000 | 235 | 0.010 |
Why?
|
| Neoplasm Transplantation | 2 | 1999 | 2016 | 0.010 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2000 | 203 | 0.010 |
Why?
|
| Comorbidity | 2 | 2008 | 10508 | 0.010 |
Why?
|
| Ethics Committees | 1 | 1998 | 51 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 1613 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1998 | 277 | 0.010 |
Why?
|
| Cholesterol | 1 | 2007 | 2904 | 0.010 |
Why?
|
| Tryptophan | 1 | 2000 | 482 | 0.010 |
Why?
|
| Ethics Committees, Clinical | 1 | 1998 | 56 | 0.010 |
Why?
|
| Hematologic Diseases | 2 | 1996 | 496 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2013 | 3801 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2000 | 555 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2000 | 423 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1998 | 350 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1997 | 306 | 0.010 |
Why?
|
| Virus Replication | 1 | 2005 | 2435 | 0.010 |
Why?
|
| Nausea | 1 | 2000 | 679 | 0.010 |
Why?
|
| Asthma | 1 | 1996 | 6234 | 0.010 |
Why?
|
| Rats | 3 | 1999 | 23742 | 0.010 |
Why?
|
| Cognition | 1 | 1995 | 6990 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2000 | 335 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2000 | 903 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1998 | 418 | 0.010 |
Why?
|
| Leucine Zippers | 1 | 1997 | 116 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 4028 | 0.010 |
Why?
|
| Platelet Aggregation | 2 | 1991 | 771 | 0.010 |
Why?
|
| Pruritus | 1 | 2000 | 380 | 0.010 |
Why?
|
| Light Coagulation | 1 | 1996 | 72 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1996 | 84 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1995 | 4021 | 0.010 |
Why?
|
| Boston | 1 | 1989 | 9326 | 0.010 |
Why?
|
| Physicians | 1 | 2014 | 4591 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1999 | 736 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 2001 | 668 | 0.010 |
Why?
|
| Naphthacenes | 2 | 1985 | 7 | 0.010 |
Why?
|
| Retinal Hemorrhage | 1 | 1996 | 95 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 621 | 0.010 |
Why?
|
| Aclarubicin | 2 | 1985 | 12 | 0.010 |
Why?
|
| Retinal Artery | 1 | 1996 | 109 | 0.010 |
Why?
|
| SEER Program | 1 | 2001 | 1450 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 825 | 0.010 |
Why?
|
| Pancreatic Hormones | 1 | 1995 | 12 | 0.010 |
Why?
|
| Diphosphonates | 1 | 2000 | 636 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1989 | 3889 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1995 | 77 | 0.010 |
Why?
|
| Smoking | 1 | 2012 | 9053 | 0.010 |
Why?
|
| Spouses | 1 | 1998 | 283 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2000 | 877 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 397 | 0.010 |
Why?
|
| Infarction | 1 | 1996 | 248 | 0.010 |
Why?
|
| Hypogonadism | 1 | 2001 | 798 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1999 | 1395 | 0.010 |
Why?
|
| Neutropenia | 1 | 2000 | 885 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 1996 | 449 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1995 | 263 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1999 | 1527 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 5035 | 0.010 |
Why?
|
| Vitreous Body | 1 | 1976 | 399 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 981 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2001 | 1119 | 0.010 |
Why?
|
| Immunization | 1 | 1998 | 1228 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1993 | 107 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1996 | 750 | 0.010 |
Why?
|
| Microcomputers | 1 | 1994 | 141 | 0.010 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 1997 | 467 | 0.010 |
Why?
|
| Thiotepa | 1 | 1993 | 66 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1997 | 1572 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 17635 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1995 | 367 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 1745 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 592 | 0.010 |
Why?
|
| Red Cross | 1 | 1992 | 12 | 0.010 |
Why?
|
| Menogaril | 1 | 1992 | 4 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2002 | 2025 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 1618 | 0.010 |
Why?
|
| Glucagon | 1 | 1995 | 532 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4920 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1995 | 569 | 0.010 |
Why?
|
| Behavioral Research | 1 | 1992 | 52 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1996 | 344 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1993 | 318 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 748 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 2612 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1995 | 897 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2001 | 1661 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 18965 | 0.010 |
Why?
|
| Heart Ventricles | 3 | 1988 | 3807 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1181 | 0.010 |
Why?
|
| Gender Identity | 1 | 1998 | 766 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 1996 | 2775 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 1995 | 617 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1996 | 918 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1994 | 15631 | 0.010 |
Why?
|
| Epinephrine | 1 | 1995 | 792 | 0.010 |
Why?
|
| Research Subjects | 1 | 1993 | 249 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1994 | 1019 | 0.010 |
Why?
|
| Metallurgy | 1 | 1991 | 95 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 2391 | 0.010 |
Why?
|
| Forecasting | 1 | 2000 | 2928 | 0.010 |
Why?
|
| Dogs | 2 | 1991 | 3839 | 0.010 |
Why?
|
| Altretamine | 1 | 1990 | 11 | 0.010 |
Why?
|
| Mining | 1 | 1991 | 93 | 0.010 |
Why?
|
| Bone Conduction | 1 | 1991 | 102 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1993 | 544 | 0.010 |
Why?
|
| Microsurgery | 1 | 1995 | 795 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2002 | 3575 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1991 | 332 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 924 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2000 | 2568 | 0.010 |
Why?
|
| Transfection | 1 | 1997 | 5774 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1993 | 790 | 0.010 |
Why?
|
| Confidentiality | 1 | 1994 | 609 | 0.010 |
Why?
|
| Auditory Threshold | 1 | 1991 | 369 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 10000 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 529 | 0.010 |
Why?
|
| Demography | 1 | 1993 | 1648 | 0.000 |
Why?
|
| Biopsy | 1 | 2000 | 6766 | 0.000 |
Why?
|
| Nutritional Status | 1 | 1997 | 1615 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1998 | 2049 | 0.000 |
Why?
|
| Eye Diseases | 1 | 1994 | 653 | 0.000 |
Why?
|
| Adenosine Diphosphate | 1 | 1989 | 422 | 0.000 |
Why?
|
| Pregnant Women | 1 | 1993 | 566 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2932 | 0.000 |
Why?
|
| Hematocrit | 1 | 1989 | 623 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1999 | 3156 | 0.000 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1989 | 422 | 0.000 |
Why?
|
| Infant | 3 | 1996 | 36192 | 0.000 |
Why?
|
| Axons | 1 | 1995 | 1674 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1999 | 3065 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1995 | 1819 | 0.000 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1997 | 2803 | 0.000 |
Why?
|
| Risk-Taking | 1 | 1992 | 1038 | 0.000 |
Why?
|
| Psychomotor Performance | 1 | 1995 | 1881 | 0.000 |
Why?
|
| Vindesine | 1 | 1986 | 12 | 0.000 |
Why?
|
| Apoptosis | 1 | 2002 | 9486 | 0.000 |
Why?
|
| Anthraquinones | 1 | 1985 | 41 | 0.000 |
Why?
|
| Organ Size | 1 | 1991 | 2254 | 0.000 |
Why?
|
| Visual Perception | 1 | 1994 | 1387 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7237 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1985 | 148 | 0.000 |
Why?
|
| Cell Cycle Proteins | 1 | 1997 | 3448 | 0.000 |
Why?
|
| Heart Conduction System | 1 | 1991 | 1007 | 0.000 |
Why?
|
| Coronary Thrombosis | 1 | 1988 | 440 | 0.000 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 1802 | 0.000 |
Why?
|
| Stroke Volume | 2 | 1989 | 5496 | 0.000 |
Why?
|
| Oxygen | 1 | 1996 | 4227 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 8181 | 0.000 |
Why?
|
| Women's Health | 1 | 1993 | 2065 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1994 | 6019 | 0.000 |
Why?
|
| Cell Line | 1 | 1997 | 15601 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1988 | 1687 | 0.000 |
Why?
|
| Perfusion | 1 | 1988 | 1373 | 0.000 |
Why?
|
| Disease Models, Animal | 2 | 2000 | 18252 | 0.000 |
Why?
|
| Angiography | 1 | 1988 | 1595 | 0.000 |
Why?
|
| Emergencies | 1 | 1989 | 1217 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1988 | 1515 | 0.000 |
Why?
|
| Birth Weight | 1 | 1991 | 2103 | 0.000 |
Why?
|
| Insulin | 1 | 1997 | 6596 | 0.000 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 7045 | 0.000 |
Why?
|
| Radiography | 1 | 1973 | 6965 | 0.000 |
Why?
|
| Depressive Disorder | 1 | 1994 | 3728 | 0.000 |
Why?
|
| Ventricular Function, Left | 1 | 1993 | 3879 | 0.000 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 4948 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1997 | 9606 | 0.000 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1991 | 2751 | 0.000 |
Why?
|
| Anaphylaxis | 1 | 1985 | 757 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1988 | 4159 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 20570 | 0.000 |
Why?
|
| Coronary Vessels | 1 | 1988 | 3096 | 0.000 |
Why?
|
| Heart Rate | 1 | 1988 | 4195 | 0.000 |
Why?
|
| Heart | 1 | 1988 | 4404 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1991 | 4671 | 0.000 |
Why?
|
| Ependymoma | 1 | 1976 | 320 | 0.000 |
Why?
|
| Rabbits | 1 | 1976 | 4772 | 0.000 |
Why?
|
| Retina | 1 | 1976 | 2659 | 0.000 |
Why?
|
| Carcinoma | 1 | 1976 | 2330 | 0.000 |
Why?
|